Click here for slides on this topic


CIMT

Abbreviation for carotid intima-media thickness.
The following content matched the glossary term: CIMT

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 - No Effect of Metformin on Atherosclerosis

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

 

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

Clinical Insights in Diabetes Newsletter July 2013

Top

Clinical Insights® in Diabetes newsletter July 2013

Carotid intima-media thickness (CIMT) change in ORIGIN-GRACE, effects of omega-3 fatty acids on CV events in the Risk and Prevention Study, canagliflozin therapy in CANTATA-D2 and CANTATA-M, weight gain and intensive therapy in ACCORD, glycemic control with single daily basal insulin plus corrective glulisine and basal bolus regimen, diurnal pattern to insulin action in type 1 diabetes.

Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: ORIGIN-GRACE

Top

Lonn EM, Bosch J, Diaz R, et al; for the GRACE and ORIGIN Investigators. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE). Diabetes Care. 2013;36(9):2466-2474. Findings from ORIGIN-GRACE showed no difference in annualized change in maximum carotid intima-media thickness for 12 carotid artery segments with insulin glargine or omega-3 fatty acid.



Slide Library Results

Search Results for: CIMT Slides Found: 11
Incidence of CVD in Patients With Type 2 Diabetes and No CVD History
CVD Event Prediction in Patients With Type 2 Diabetes and No CVD History
ORIGIN-GRACE: Design
ORIGIN-GRACE: Primary and Secondary Outcomes
ORIGIN-GRACE: Select Baseline Characteristics
ORIGIN-GRACE: No Difference in Annualized Change in Max CIMT for 12 Carotid Artery Segments with Glargine or Omega-3 Fatty Acid
ORIGIN-GRACE: Glargine, Not Omega-3 Fatty Acid, Improves Annualized Change in Max CIMT
ORIGIN-GRACE: No Difference in Annualized Change in Max Far Wall CIMT for Glargine or Omega-3 Fatty Acid
ORIGIN-GRACE: Major Cardiovascular Events
ORIGIN-GRACE: Summary of Findings
ORIGIN-GRACE: Eligibility Criteria and Trial Profile